Ahmed et al., 2007 - Google Patents
Regression of experimental medulloblastoma following transfer of HER2-specific T cellsAhmed et al., 2007
View PDF- Document ID
- 3799772427752080464
- Author
- Ahmed N
- Ratnayake M
- Savoldo B
- Perlaky L
- Dotti G
- Wels W
- Bhattacharjee M
- Gilbertson R
- Shine H
- Weiss H
- Rooney C
- Heslop H
- Gottschalk S
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
Medulloblastoma is a common malignant brain tumor of childhood. Human epidermal growth factor receptor 2 (HER2) is expressed by 40% of medulloblastomas and is a risk factor for poor outcome with current aggressive multimodal therapy. In contrast to breast …
- 101700025368 ERBB2 0 title abstract description 189
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmed et al. | Regression of experimental medulloblastoma following transfer of HER2-specific T cells | |
| Ahmed et al. | HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors | |
| JP6997744B2 (en) | Methods and compositions for cell immunotherapy | |
| Walker et al. | Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase | |
| Song et al. | CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo | |
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| Song et al. | A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity | |
| Ahmed et al. | Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression | |
| Krenciute et al. | Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T cells to IL13Rα2-positive glioma | |
| Tang et al. | T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo | |
| US10647997B2 (en) | Modified effector cell (or chimeric receptor) for treating disialoganglioside GD2-expressing neoplasia | |
| Thomas et al. | An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers | |
| Seyfrid et al. | CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment | |
| EP3612568B1 (en) | Cell | |
| Schutsky et al. | Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor | |
| JP2020500530A (en) | Synthetic immune receptors and methods of use | |
| KR20140023931A (en) | Method and compositions for cellular immunotherapy | |
| Rajabzadeh et al. | A VHH-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells | |
| CN107523547A (en) | A kind of CAR T cells of high efficiency stable expression inhibiting antibody and application thereof | |
| CN117802051A (en) | Modified cells and compositions | |
| Lo et al. | Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor | |
| Nasiri et al. | T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts | |
| Zhao et al. | An NK cell line (NK92-41BB) expressing high levels of granzyme is engineered to express the high affinity chimeric genes CD16/CAR | |
| Turatti et al. | Highly efficient redirected anti‐tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor | |
| Kennewick et al. | Nonsignaling extracellular spacer regulates tumor antigen selectivity of CAR T cells |